![Photo of affected lot - PROPOFOL Injectable Emulsion, USP (contains benzyl alcohol) 100 mL Single Patient Use, Glass Fliptop Vial. Lot DX9067 [Credit: Pfizer].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Propofol-recall-300x278.jpg)
![Photo of affected lot - PROPOFOL Injectable Emulsion, USP (contains benzyl alcohol) 100 mL Single Patient Use, Glass Fliptop Vial. Lot DX9067 [Credit: Pfizer].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Propofol-recall-e1657792683882.jpg)
news
Hospira recalls lot of Propofol Injectable Emulsion
The voluntary US-wide recall of Lot DX9067 of Propofol Injectable Emulsion, USP is due to the possible presence of visible particulate with potentially harmful effects.
List view / Grid view
Hospira Inc.
news
HPAPI market to value $27bn by 2025
Driven by oncology drug demand, the highly potent active pharmaceutical ingredients (HPAPIs) market is anticipated to grow by $7bn in three years.
news
Bacteriostatic Water recalled due to a potential lack of sterility assurance
Bacteriostatic Water is being recalled because of a lack of sterilisation confirmation for some vials.
news
FDA approves first epoetin alfa biosimilar for the treatment of anaemia
The FDA has approved Retacrit as a biosimilar to Epogen/Procrit for the treatment of anaemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection...
